Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to intimation dated 24th February,2025, Medi-Caps has informed that the United States Food & Drug Administration (USFDA) conducted an inspection at the manufacturing facility of Wholly Owned Subsidiary Company, Medgel at Pithampur, Madhya Pradesh, from 17th to 21st February, 2025 and it has informed that the company has received a communication from US FDA indicating that the inspection classification of this facility as ‘Voluntary Action Indicated’ (VAI). FDA has concluded that this inspection is ‘closed’ under 21 CFR 20.64 (d) (3). The above information will also be available on the website of the Company at www.medicaps.com.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| BASF India | 3739.05 |
| Tata Chemicals | 707.80 |
| SRF | 2541.95 |
| Pidilite Inds. | 1402.25 |
| Deepak Nitrite | 1731.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: